Company: RGNT
Filing Date: 2025-05-05
Form Type: F-1/A
Source: 0001213900-25-039589
Chunk: 230

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-05-05
Form: F-1/A
Chunk 230
---
     |           |     |           |
| Proceeds, before expenses, to us |     | $         |     |           |     |           |

| (1) | We have agreed to pay a non-accountable expense allowance to the Representative equal to 1.0% of the gross proceeds received in this offering (excluding proceeds received from exercise of the Representative’s over-allotment option) which is not included in the underwriting discounts and commission. |

We have paid an expense deposit
of $35,000 to the Representative, which will be applied against the Representative’s actual out-of-pocket accountable expenses that
are payable by us in connection with this offering and such expense deposit shall be reimbursed to the Company to the extent any portion
thereof is not actually incurred in compliance with FINRA Rule 5110(g)(4)(A). We have agreed to reimburse the Representative for the fees
and expenses of its legal counsel in connection with the offering in an amount not to exceed $125,000, the fees and expenses related to
the use of Ipreo’s book building, prospectus tracking and compliance software for the offering in the amount of $29,500, up to $15,000
for background checks of our officers and directors, the costs associated with bound volumes of the public offering materials as well
as commemorative mementos and lucite tombstones in an amount not to exceed $3,000, data services and communications expenses up to $10,000,
the actual accountable “road show” expenses up to $10,000 and the costs of market making and trading and clearing firm settlement
expenses up to $30,000; provided however that the aggregate accountable expenses reimbursement will not exceed $175,000.

We expect that the expenses
of this offering payable by us, not including underwriting discounts and commissions, will be approximately $1,000,000.

Representative’s Warrants

We have agreed to
issue to the Representative, upon the consummation of this offering, warrants to purchase up to an aggregate amount of Ordinary
Shares equal to an aggregate of up to (representing 5.0% of
the Ordinary Shares sold in this offering, including any Ordinary Shares sold upon exercise of the Representative’s
over-allotment option), or the Representative’s Warrants. The Representative’s Warrants are exercisable at a per share
price equal to $ (representing 125.0% of the public offering price per share in this offering). The Representative